Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

In this study, injecting dermal sheath cup cells into affected areas of pattern hair loss improved hair thickness and patient-reported hair appearance in 62.9% of the participants, with better results in women, without serious side effects.

This study found that 5% minoxidil topical foam used once daily for 24 weeks was well tolerated and significantly improved hair regrowth and scalp coverage in women with female pattern hair loss compared to vehicle foam.